Human immunodeficiency virus vaccine an update

Journal of Oral and Maxillofacial Pathology

Volumn 17, Issue 1, 2013, Pages 76-81

  Beena, V T ^b   Choudhary, Kanaram ^a   Rajeev, R ^b   Sivakumar, R ^b   Heera, R ^c   Padmakumar, S K ^a  

^a Oral and Maxillofacial Surgery   (India)

^b GOVERNMENT DENTAL COLLEGE   (India)

^c Government Dental College   (India)

Author keywords

Acquired immuno deficiency syndrome; cell mediated immunity; human immunodeficiency virus vaccine

Indexed keywords

EID: 84877739033     PISSN: 0973029X     EISSN: 1998393X     Source Type: Journal    
DOI: 10.4103/0973-029X.110741     Document Type: Article

References (29)

1. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981;305:1425-31. (Pubitemid 12240076)
2. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Montagnier L, et al. Isolation of a T lymphotropic retrovirus from a patient at risk for acquired immunedeficiency syndrome (AIDS). Science 1983;220:868-71. (Pubitemid 13080157)
3. Kovacs JA, Vasudevachari MB, Easter M, Davey RT, Falloon J, Polis MA, et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. J Clin Invest 1993;92:919-28. (Pubitemid 23262415)
4. Murphey-Corb M, Martin LN, Davison-Fairburn B, Montelaro RC, Miller M, West M, et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989;246:1293-7. (Pubitemid 20066712)
5. Arthur LO, Bess JW Jr, Sowder RC 2nd, Benveniste RE, Mann DL, Chermann JC, et al. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science 1992;258:1935-8. (Pubitemid 23026732)
6. Polyanskaya N, Sharpe SA, Cook N, Leech S, Cranage MP. Infection of macaques with simian immunodeficiency virus induces a species-specific antibody response to major histocompatibility complex class I and class II molecules. J Gen Virol 2003;84:1671-6. (Pubitemid 36805901)
7. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990;345:622-5.
8. Ready T. AIDSVAX flop leaves vaccine field unscathed. Nat Med 2003;9:376. (Pubitemid 36460052)
9. Ahn S, Sung Y. AIDS vaccine development: The past, the present, and the future. Immune Netw 2009;9:1-3.
10. Patterson LJ, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B, et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J Virol 2003;77:8607-20. (Pubitemid 36936072)
11. Davenport MP, Ribeiro RM, Chao DL, Perelson AS. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol 2004;78:11340-51. (Pubitemid 39299675)
12. Slobod KS, Coleclough C, Brown SA, Stambas J, Zhan X, Surman S, et al. Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary AIDS Res Ther 2005;2:3.
13. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8cell epitopes. J Virol 2006;80:4717-28.
14. Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao HX, Ma BJ, et al. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus envimmunogen. J Virol 2006;80:6745-56. (Pubitemid 44025174)
15. Hanke T, Goonetilleke N, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA-and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 2007;88:1-12. (Pubitemid 46085108)
16. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008;82:7369-78. (Pubitemid 352031205)
17. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-5. (Pubitemid 34087555)
18. Steinbrook R. One step forward, two steps back: Will there ever be an AIDS vaccine N Engl J Med 2007;357:2653-5.
19. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009;5:e1000433.
20. Carnero E, Li W, Borderia AV, Moltedo B, Moran T, García-Sastre A. Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol 2009;83:584-97.
21. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20.
22. Lori F. DermaVir: A plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS. Expert Rev Vaccines 2011;10:1371-84.
23. Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, Bakare N, et al. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 2005;19:35-43. (Pubitemid 40111016)
24. Shimada M, Wang HB, Kondo A, Xu XP, Yoshida A, Shinoda K, et al. Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy. Gene Ther 2009;16:218-28.
25. Persaud D, Luzuriaga K, Ziemniak C, Muresan P, Greenough T, Fenton T, et al. Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4cell latent HIV reservoir. AIDS 2011;25:2227-34.
26. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, et al. Dendritic cell-targeted protein vaccines: A novel approach to induce T-cell immunity. J Intern Med 2012;271:183-92.
27. Koopman G, Mortier D, Hofman S, Mathy N, Koutsoukos M, Ertl P, et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: Increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J Gen Virol 2008;89:540-53. (Pubitemid 351622452)
28. Kulkarni H, Marconi VC, Agan BK, McArthur C, Crawford G, Clark RA, et al. Role of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy. PLoS One 2008;3:e3671.
29. Bansal A, Jackson B, West K, Wang S, Lu S, Kennedy JS, et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008;82:6458-69. (Pubitemid 351875123)